US · SMTI
Sanara MedTech Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Fort Worth, TX 76102
- Website
- sanaramedtech.com
Price · as of 2024-12-31
$19.73
Market cap 182.64M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $201.06 | +919.06% |
| Intrinsic Value(DCF) | $625.35 | +3,069.54% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $71.00 | $156.13 | $2,663.82 | $0.00 | $0.00 |
| 2011 | $26.00 | $1,973.00 | $335,940.28 | $0.00 | $0.00 |
| 2012 | $7.00 | $189.22 | $836.27 | $0.00 | $98.29 |
| 2013 | $11.00 | $112.56 | $396.84 | $0.00 | $0.00 |
| 2014 | $6.00 | $152.39 | $77.31 | $0.00 | $0.00 |
| 2015 | $8.00 | $412.05 | $126.08 | $0.00 | $0.00 |
| 2016 | $7.00 | $1,640.69 | $791.61 | $0.00 | $0.00 |
| 2017 | $6.00 | $1,434.83 | $714.84 | $1.14 | $6.52 |
| 2018 | $5.00 | $1,787.36 | $32.95 | $0.00 | $0.00 |
| 2019 | $11.00 | $5,634.58 | $637.52 | $0.00 | $0.00 |
| 2020 | $33.25 | $56.57 | $671.19 | $0.00 | $0.00 |
| 2021 | $26.54 | $36.30 | $1,432.43 | $0.00 | $0.00 |
| 2022 | $40.52 | $50.68 | $9,554.01 | $0.00 | $0.00 |
| 2023 | $36.52 | $110.92 | $20,877.05 | $2.38 | $0.00 |
| 2024 | $33.01 | $201.06 | $5,312.43 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Sanara MedTech Inc.'s (SMTI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $201.06
- Current price
- $19.73
- AI upside
- +919.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$625.35
+3,069.54% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SMTI | Sanara MedTech Inc. | $19.73 | 182.64M | +919% | +3,070% | — | — | -28.26 | 7.11 | 3.23 | -159.37 | -23.70 | -53.81 | 90.61% | -7.75% | -11.15% | -23.53% | -12.52% | -12.24% | 0.82 | -2.15 | 2.18 | 1.92 | -8.82 | 11923.00% | 3336.00% | -9279.00% | -0.09% | 0.00 | -0.47% | 0.00% | 0.00% | 0.00% | -44.15 | -1171.43 | 3.42 | 3.79 |
| HITI | High Tide Inc. | $2.53 | 222.23M | +702% | -58% | — | — | -6.02 | 3.49 | 0.51 | -29.64 | -0.58 | -7.28 | 25.85% | -2.43% | -8.54% | -43.96% | -8.04% | -17.05% | 1.71 | -1.08 | 1.37 | 0.54 | -7.42 | 103761.00% | 1372.00% | -4795.00% | 4.40% | 0.24 | 7.47% | 0.46% | -2.80% | 0.46% | -28.19 | 30.34 | 0.69 | 1.39 |
| LFMD | LifeMD, Inc. | $2.67 | 128.52M | +1,008% | +2,300% | — | — | -10.27 | -35.07 | 0.91 | -27.43 | — | -9.02 | 88.67% | -7.60% | -8.89% | 1891.64% | 123.73% | -28.61% | -4.58 | -7.40 | 0.81 | 0.72 | 1.49 | -2429.00% | 3927.00% | 677408.00% | 3.11% | 0.29 | -45.81% | 1.61% | -16.60% | 1.61% | -11.30 | 30.53 | 0.86 | -1.05 |
| NEO | NeoGenomics, Inc. | $9.83 | 255.21M | +138% | -61% | — | — | -2.25 | 0.29 | 0.33 | 318.65 | -6.35 | 9.47 | 38.85% | -9.09% | -14.85% | -12.42% | -5.70% | -7.21% | 0.56 | -17.61 | 4.26 | 3.61 | 179.17 | 3548.00% | 1011.00% | -3602.00% | -8.95% | 0.06 | -1.92% | 0.00% | 0.00% | 0.00% | -8.41 | -25.53 | 0.76 | 0.46 |
| OMI | Owens & Minor, Inc. | $2.68 | 207.07M | +942% | +49% | — | — | -2.12 | 1.36 | 0.07 | 48.40 | -0.28 | -0.72 | 20.74% | -1.94% | -3.39% | -48.70% | -7.35% | -7.44% | 3.79 | -1.44 | 1.08 | 0.39 | 35.40 | 76000.00% | 355.00% | -11251.00% | -8.69% | 0.09 | -2.36% | 0.00% | 0.00% | 0.00% | -13.75 | -42.87 | 0.27 | 2.30 |
| SGHT | Sight Sciences, Inc. | $5.16 | 272.82M | +483% | -76% | — | — | -2.30 | 1.35 | 1.48 | -0.83 | — | 1.35 | 85.50% | -63.27% | -64.49% | -49.59% | -403.80% | -33.29% | 0.46 | -10.84 | 9.04 | 8.48 | 1.74 | -965.00% | -147.00% | -5261.00% | -19.22% | -1.44 | -181.68% | 0.00% | 0.00% | 0.00% | -0.76 | -1.69 | 0.48 | -1.67 |
| TBRG | TruBridge, Inc. | $19.29 | 289.52M | +494% | -41% | — | — | -19.81 | 2.40 | 1.18 | 16.24 | — | -3.32 | 50.81% | 1.94% | -5.97% | -11.59% | 1.86% | -4.95% | 1.04 | 0.41 | 1.70 | 1.34 | 4.65 | -5619.00% | 95.00% | -15833.00% | 3.22% | 0.61 | 3.65% | 0.00% | 0.00% | 9.23% | 85.50 | 43.52 | 1.66 | 2.06 |
| TRDA | Entrada Therapeutics, Inc… | $11.93 | 455.96M | +114% | -46% | — | +2,115% | -3.36 | 1.58 | 19.01 | -1.67 | — | 1.58 | 83.89% | -621.13% | -565.48% | -39.13% | -244.32% | -31.81% | 0.17 | — | 12.53 | 12.09 | 0.28 | -30655.00% | -8794.00% | 18973.00% | -26.81% | -5.26 | -200.46% | 0.00% | 0.00% | 0.10% | -1.51 | -1.84 | 9.38 | 2.64 |
| VMD | Viemed Healthcare, Inc. | $8.70 | 337.44M | +443% | +545% | -54% | -1% | 25.48 | 2.21 | 1.30 | 6.62 | 212.30 | 2.98 | 59.40% | 7.98% | 5.02% | 9.30% | 10.88% | 6.87% | 0.05 | 23.07 | 1.42 | 1.14 | -0.25 | 1200.00% | 2254.00% | -9311.00% | 0.45% | 1.05 | 1.14% | 0.00% | 0.00% | 3.17% | 15.64 | 212.43 | 1.25 | 6.40 |
| XGN | Exagen Inc. | $3.62 | 82.04M | +641% | +1,119% | — | — | -3.89 | 6.16 | 1.06 | -5.36 | — | 6.16 | 59.51% | -24.51% | -27.17% | -93.78% | -136.76% | -29.74% | 2.41 | -6.10 | 2.70 | 2.21 | -0.09 | -3806.00% | 589.00% | -978.00% | -23.46% | -0.98 | -138.35% | 0.00% | 0.00% | 0.00% | -4.38 | -4.33 | 1.07 | -7.36 |
About Sanara MedTech Inc.
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
- CEO
- Seth D. Yon
- Employees
- 141
- Beta
- 1.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($625.35 ÷ $19.73) − 1 = +3,069.54% (DCF, example).